In this video Dr Catana, with Beth Israel Deaconess Medical Center in Boston, provides highlights of presentations and panel discussions at the American Association for the Study of Liver Diseases meeting on hepatocellular carcinoma.
In this video, Dr Bonder, medical director of liver transplantation at Beth Israel Deaconess Medical Center and assistant professor of medicine at Harvard Medical School, discusses promising developments in medical therapies for patients with primary biliary cholangitis that were revealed at the recent virtual annual meeting of the American Association for the Study of Liver Diseases.
In this video, Dr Fricker, from Beth Israel Deaconess Hospital in Boston, discusses sessions on managing patients with cirrhosis held at the recent virtual meeting of the American Association for the Study of Liver Diseases.
In this video, Michael Curry, MD, from Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, reviews presentations from the American Association for the Study of Liver Diseases on the management of hepatorenal syndrome.
Hirsh Trivedi, MD, from Beth Israel Deaconess Medical Center in Boston, provides an overview of presentations given at the American Association for the Study of Liver Diseases annual meeting on the prevalence, diagnosis, and management of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
In this video, Lauren Yang, MD, from Beth Israel Deaconess Medical Center, discusses what learned at the recent American Association for the Study of Liver Diseases annual meeting about research into managing hepatitis B.
Patients with viral hepatitis-related cirrhosis are known to be at increased risk of hepatocellular carcinoma and cholangiocarcinoma, and early detection greatly improves outcomes. Yet far too few patients are not being screened, said Amit Singal, MD, from UT-Southwestern Medical Center, at the American Association for the Study of Liver Diseases Annual Meeting.
Early recognition and management of acute kidney injury are critical to optimize outcomes among patients with advanced liver disease.
Big decreases in the cost of gene sequencing is making the delivery of precision care to patients with liver disease increasingly feasible, says Scott L. Friedman, MD, at the virtual 2020 Liver Meeting.
Gastroenterologists and hepatologists must carefully assess and interpret studies of iron deposition to guide treatment of patients with both genetic and secondary hemochromatosis, Vinday Sundaram, MD, explained at the American Association for the Study of Liver Diseases.